Brazilian surveillance records of patients hospitalised with confirmed influenza were analysed from 2023 to October 2025, as vaccine uptake fell from about 70% to 40-50%. Two trivalent doses within a calendar year were associated with 32% lower in-hospital mortality and 52% fewer ICU admissions. A single dose was associated with reductions of 10-13% across the same measures.
Why it is interesting: All patients were already in hospital, so the comparison is of severity rather than of infection.
Abstract — the authors' own words, CC BY
Introduction
Despite a significant increase in influenza burden in Brazil in 2025, influenza vaccine effectiveness has not included the key end-of-winter period so far. Methods:
The key exposure measure was the number of trivalent influenza vaccine doses received within a calendar year. In-hospital mortality and length of stay, use of the intensive care unit (ICU), and ICU stay were outcome measures. Secondary data from January 2003 to October 2025 were retrieved and analysed by Poisson regression. Results
Influenza vaccine uptake among SARI-hospitalised patients dropped from about 70% in 2023 to a 40-50% level in 2024 and 2025. A single vaccine dose reduced outcomes by 10-13% compared to unvaccinated patients. Two doses per year significantly reduced mortality (32%), ICU admissions (52%), and ICU stay (28%). Conclusion
Two doses of influenza vaccine were moderately effective in decreasing in-hospital mortality and stay among SARI-hospitalised influenza patients. Including 50-59-year-olds in a priority vaccination group may significantly reduce influenza-related adverse outcomes.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.